Science

Rishabh Jain: Rare but Deadly – ICIs Can Trigger Myocarditis and Myositis

Rishabh Jain/X

Sep 3, 2025, 09:13

Rishabh Jain: Rare but Deadly – ICIs Can Trigger Myocarditis and Myositis

Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X about a paper by Joe-Elie Salem et al. published in the European Heart Journal:

“Rare but deadly: Immune checkpoint inhibitors (ICI) can trigger myocarditis and myositis.

French nationwide cohort (n=172,363) reports:
Incidence: 0.7–0.9% at 6 months
Highest in thymic ca (7.1%)
Major risk factors: thymic disorders, myasthenia, melanoma, combo ICI, age >85 y
1-month fatality: ~20%
Take-home: ICI myotoxicity = strongest predictor of early mortality (HR 3.5 at 30d).

Salem JE, et al. Eur Heart J. 2025.”

Title: Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study

Authors: Joe-Elie Salem, Aya Ajrouche, Antoine Rozes, Sandrine Pinto, Yann De Rycke, Florence Tubach

You can read the Full Article in the European Heart Journal.

Rishabh Jain: Rare but Deadly - ICIs Can Trigger Myocarditis and Myositis

More posts featuring Rishabh Jain.

Antoine Rozes Aya Ajrouche cancer Florence Tubach ICI Immune Checkpoint Inhibitors Joe-Elie Salem myocarditis myositis OncoDaily Oncology Rishabh Jain Sandrine Pinto Yann De Rycke

100 Oncologists, One Community: Reflections from the First ESO College Convention

Gevorg Tamamyan: "Fertility News" is on the Way

JCO on a Jamaican Beach: The Journey of Joyson Karakunnel

Patrick Soon-Shiong: NK cells matter!

Anas Younes Has Been Appointed Chief Medical Officer at AstraZeneca